Exicure (XCUR) Current Deferred Revenue (2016 - 2022)
Exicure's (XCUR) quarterly Current Deferred Revenue came in at $21.8 million in Q3 2022, up 55.36% YoY from $14.0 million in Q3 2021, and up 47.57% on a QoQ basis from $14.8 million in Q2 2022.
Exicure (XCUR) Current Deferred Revenue (2016 - 2022) Analysis & Trends
Exicure (XCUR) has 6 years of Current Deferred Revenue data on file, last reported at $21.8 million in Q3 2022.
- Quarterly Current Deferred Revenue rose 55.36% year-over-year to $21.8 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $21.8 million (up 55.36% YoY) and the FY2021 annual result came in at $17.3 million, changed N/A from the prior year.
- Current Deferred Revenue grew to $21.8 million in Q3 2022, from $14.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $26.3 million in Q1 2022 to a low of $14000.0 in Q3 2019.
- A 4-year average of $11.2 million and a median of $10.9 million in 2020 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2020 — Current Deferred Revenue soared 60464.29% — and 2021, when it slumped 53.25%.
- Tracing XCUR's Current Deferred Revenue over 4 years: stood at $14000.0 in 2019, then soared by 60464.29% to $8.5 million in 2020, then jumped by 104.23% to $17.3 million in 2021, then rose by 25.74% to $21.8 million in 2022.
- The last three Current Deferred Revenue figures came in at $21.8 million (Q3 2022), $14.8 million (Q2 2022), and $26.3 million (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 21.77 Mn |
| Jun 30, 2022 | 14.76 Mn |
| Mar 31, 2022 | 26.26 Mn |
| Dec 31, 2021 | 17.32 Mn |
| Sep 30, 2021 | 14.02 Mn |
| Jun 30, 2021 | 7.27 Mn |
| Mar 31, 2021 | 7.35 Mn |
| Sep 30, 2020 | 8.48 Mn |
| Jun 30, 2020 | 10.88 Mn |
| Mar 31, 2020 | 15.71 Mn |
| Sep 30, 2019 | 14,000.00 |
| Jun 30, 2019 | 541,000.00 |
| Mar 31, 2019 | 975,000.00 |
| Dec 31, 2017 | 1.03 Mn |
| Dec 31, 2016 | 8.28 Mn |